Effect of albendazole administration on pharmacokinetic aspects of tylosin in lactating goats.
Tylosin concentrations and its disposition kinetics in serum, urine, and milk of lactating goats following a single intravenous (i.v.) or intramuscular (i.m.) injection (10 mg kg(-1) b.wt.) were carried out using high performance liquid chromatography (HPLC).The concentration-time curve of tylosin after i.v. injection could be described by a two-compartment open model. Tylosin was rapidly distributed and eliminated from goat's bodies with t(1/2(beta)) value of 1.25 h. The V((d)) was less than one litre/kg and the MRT was 1.40 h. Concomitant administration with albendazole decreased tylosin concentrations in serum after its i.v. injection and the MRT was 1.17 h. The AUC and AUMC showed a significant decrease in goats given albendazole prior to injection as compared with those given tylosin only. Following i.m. administration, the absorption half-life and the corresponding t(max) revealed rapid absorption rate with systemic bioavailability (F%) of 76.2 %. Albendazole when given concurrently with tylosin decreased its serum concentrations due to lower bioavailability (43.25 %). Following i.v. or i.m. injection, tylosin was excreted rapidly in urine in concentration much higher than those determined in serum and milk. Tylosin administered in goats pretreated with albendazole was excreted at lower concentration in urine, with a significant decrease from 1(st) to 10(th) hours as compared with animals given tylosin only. Following i.v. or i.m. administration of tylosin, the drug was excreted in high concentrations in milk. A significant decrease in milk concentrations was reported in goats pretreated with albendazole.
Atef
M
M
Department of Pharmacology, Faculty of Veterinary Medicine, Cairo University, Giza, 12211-Egypt. atefshehata@live.com
Ramadan
A
A
Darwish
A S
AS
Fahim
Aisha M M
AM
D000284:Administration, Oral; D015766:Albendazole / Q000008:administration & dosage*; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D019540:Area Under Curve; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid; D004347:Drug Interactions; D005260:Female; D006041:Goats; D006207:Half-Life; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007774:Lactation / Q000378:metabolism*; D008657:Metabolic Clearance Rate; D008892:Milk / Q000378:metabolism; D008954:Models, Biological; D015645:Tylosin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine
D000871:Anthelmintics; D000900:Anti-Bacterial Agents; D015766:Albendazole; D015645:Tylosin